Welcome  |   Program  |   Registration  |   Hotel  |   Support and Exhibitors
Meeting Program
Continuing Medical Education (CME) is jointly provided by
the American Association for Cancer Research (AACR) and the
Association of American Cancer Institutes (AACI)
All sessions will be held in the Wright Ballroom, Lobby Level, except where indicated.
Sunday, September 30
8:00-10:00 am

Corporate Roundtable Meeting (closed meeting)

11:00 am

Meeting Registration Begins
Wright Foyer, Lobby Level

11:00 am

Exhibits Open
Wright Foyer, Lobby Level

General Session

12:00 pm

Welcome and AACI Business Meeting

President’s Report
Dr. Stanton L. Gerson
Case Comprehensive Cancer Center

Executive Director’s Report
Ms. Barbara Duffy Stewart
Association of American Cancer Institutes

Treasurer’s Report
Mr. Jeff Walker
City of Hope

Program Chair’s Report
Dr. Randall F. Holcombe
University of Hawai'i Cancer Center
University of Hawai'i at Mānoa

CCAF Report
Mr. Alex Zafirovski
The Robert H. Lurie Comprehensive Cancer Center
Northwestern University

1:00 pm

A Ten-Year Outlook for Academic Cancer Centers
Academic cancer centers have made remarkable strides in recent years that have enhanced their ability to deliver better care to patients; from the increased availability of genetic information sequencing to advances in the areas of targeted therapy, immunotherapy, and cancer screening technology. To help centers sustain that progress and build on their decades of learning, speakers in this session will share their perspectives and predictions for how academic cancer centers will evolve over the next ten years. Topics of conversation will include maintaining research and managing innovation; distributed care; changes in reimbursement and points of care, and use of electronic methods of care delivery.

2:00 pm

New President's Initiative

2:15 pm


2:45 pm

Cancer is a Global Issue: Partnerships with the Developing World
A growing number of cancer centers have established partnerships with countries in the developing world, with involvement extending to both research and the direct delivery of care. This session will include an overview of cancer research and treatment in the developing world, as well as details about how centers are interacting with specific countries including Kenya, Malawi, and Cuba, where US sanctions are creating unique challenges for cancer research collaborations.

4:00-6:00 pm

6th AACI Physician Clinical Leadership Initiative Meeting
Avoiding Physician Burnout: Strategies for Promoting Personal and Professional Satisfaction
Whether diagnosing cancer or managing related complications, devising personalized treatment plans, providing critical support in the face of daunting illness, or myriad other intellectually and emotionally stimulating tasks, caring for cancer patients can be immensely rewarding. Despite its rewards, caring for cancer patients can also be a stressful calling. From life and death decision-making to keeping pace with constantly evolving science, productivity requirements, and regulatory and administrative burdens, oncology practice takes its toll physically and emotionally. At this 6th Annual Meeting of the AACI Physician Clinical Leadership Initiative, panelists will discuss the professional and personal consequences associated with physician burnout and will suggest strategies for avoiding downturns and promoting personal and professional satisfaction.

5:00-5:30 pm

CCAF Business Meeting
(closed session for members of CCAF)
Location TBD

6:00-7:30 pm

Welcome Reception - Sponsored by Forte
Garden Terrace

Monday, October 1
7:00 am

General Breakfast
Sullivan Ballroom, Lobby Level

7:00 am

Exhibits Open
Wright Foyer, Lobby Level

8:00 am

AACI Presidential Initiative Update: Network Care
Managing cancer center networks is a complex task involving many moving parts; without a clear roadmap, a network can become unmanageable. AACI’s Network Care Initiative aims to help AACI’s academic cancer centers paint an accurate picture of their impact on cancer care across the regions they serve. AACI President Dr. Stanton Gerson will provide an update on the initiative, including a summary of final survey results. This session will cover topics related to network management including: standardization of care and the use of care paths (suggested diagnostic and treatment pathways); collaborating with other centers and community sites; working with varied employment network models; and providing access to clinical trials.

Dr. Stanton L. Gerson
Case Comprehensive Cancer Center

8:45 am

Big Data in Cancer Care (concurrent)
Sullivan Ballroom, Lobby Level
As Big Data changes the face of cancer research and treatment, the vast amount of information--and wide variety of sources for that information--are presenting significant challenges in collecting and integrating data. This session convenes commercial and academic players in the Big Data arena with an eye toward enhancing dialogue and developing stronger linkages that could lead to expanded information-sharing and improved patient care.

8:45 am

CCSG Session TBD (concurrent)

10:00 am


10:15 am

Cancer Health Economics
In the face of persistent shifts in the political landscape and health care marketplace, cancer centers are confronting an expanding array of challenges. Speakers in this session will discuss improving patient access to cancer drugs, financial toxicity and patient adherence to treatment plans, and public perception and values in approving cancer drugs.

11:30 am

Distinguished Scientist
Charles M. Perou, PhD, a renowned breast cancer researcher at the UNC Lineberger Comprehensive Cancer Center, is being recognized by AACI for his accomplishments in the field of precision medicine and for groundbreaking research in the characterization of the diversity of human tumors. The clinical value of his work leading to the discovery of the “Intrinsic Subtypes of Breast Cancer” has had a profound impact on the treatment of breast cancer patients worldwide. Dr. Perou’s talk will focus on sequencing studies for gene expression analysis, specifically, on research results showing the value of sequencing-based approaches in breast and lung cancers.

12:30 pm

Sullivan Ballroom, Lobby Level

1:30 pm

Networking, Dessert, & CRI Posters
Wright Foyer, Lobby Level

2:30 pm

Comprehensive Cancer Patient Support
Just as a spouse, children, relatives and friends can constitute an invaluable network of support for a loved one with cancer, cancer centers are increasingly recognizing the value to patients of a support network of experts drawn from fields as disparate as mental health, geriatric care, pain and symptom management, survivorship and counseling for financially challenged patients. Over time, the field has transformed from palliative care to alternative medicine to, today, an expansive umbrella of research interests and treatment approaches that underpin nearly all cancer center operations. Panelists will explore programs that cancer centers have developed to enhance comprehensive support and deliver multidisciplinary care for the patient with cancer.

3:45 pm


4:00 pm

CCSG Nuts and Bolts (concurrent)
Optimal compliance with NCI Cancer Center Support Grant (CCSG) guidelines will be explored in this session, with particular focus on selected cancer centers that have recently completed core grant submissions.  The practical implications of preparing a CCSG competing renewal will be reviewed, and advice will be offered regarding different approaches for free-standing versus matrix cancer centers.

4:00 pm

Tumor Microenvironment (concurrent)
Sullivan Ballroom, Lobby Level
The tumor microenvironment is a complex network of cells and extracellular matrix proteins that support tumor development and progression. As we move toward personalized medicine in cancer care, understanding the influence of structural entities on gene expression and communication among functionally distinct but phenotypically identical cells within the environment is essential to effectively translating individualized therapy to patients. This session will focus on the impact of matrix rigidity on gene expression by the multiplicity of cells in the tumor microenvironment.  The session will also highlight the impact of single cell genomics and transcriptomics and its potential to impact patient care.

5:15 pm

Sessions End

8:30-11:00 pm

Hospitality Suite - Sponsored by Complion
Pullman/The Dining Car, Lobby Level

Tuesday, October 2
7:00 am

General Breakfast
Sullivan Ballroom, Lobby Level

7:00 am

Topic Specific Breakfast Roundtable Discussions
Location TBD

7:00 am

Exhibits Open
Wright Foyer, Lobby Level

General Session

8:00 am

NCI Director’s Report
The director of the National Cancer Institute (NCI) will highlight programmatic priorities, and identify funding opportunities to support ongoing collaborations between the NCI and academic cancer centers.

8:45 am

Guidelines-Driven Review: Conveying Comprehensiveness, Training and Community Engagement
As cancer centers continue to wrestle with revised guidelines for the National Cancer Institute’s Cancer Center Support Grant application, some metrics that help to determine funding levels are proving problematic. Panelists will discuss comprehensiveness, training, and community engagement, with an eye toward clarifying definitions, NCI’s perspective and expectations, and factors that drive the scoring of centers’ performance in these areas.

9:45 am


10:00 am

AACI Clinical Research Initiative (CRI) Update
In July, AACI’s Clinical Research Initiative (CRI) convened its 10th annual meeting with the program theme: "Leveraging Change to Advance Cures for Cancer Patients".

10:30 am

Best Practices in Cell Therapy/CAR-T
In these still early days of CAR T-cells and other forms of adoptive cell transfer—the Food and Drug Administration granted its first approvals for CAR T-cell therapy in 2017—more cancer centers are stepping up their efforts in the field or considering doing so. Among the decisions being weighed are whether to develop cells in-house, procure them from commercial entities, or embrace a hybrid approach. Panelists will consider that issue as well as the nuts and bolts of developing a CAR T-cell therapy program, including intake and management issues, standard operating procedures and regulatory requirements.

11:30 am

Update on the NCI Cancer Centers Program
This session provides an opportunity for an open dialogue with the director of the NCI Office of Cancer Centers about the requirements and funding of the Cancer Center Support Grant.

12:15 pm


Program Subject to Change

Continuing Medical Education

Joint Providership Statement
Jointly provided by the American Association for Cancer Research and the Association of American Cancer Institutes.

This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of the American Association for Cancer Research and the Association of American Cancer Institutes. The American Association for Cancer Research is accredited by the ACCME to provide continuing medical education for physicians.

Credit Designation
The American Association for Cancer Research designates this live activity for a maximum of 15.00 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Credit certification for individual sessions may vary, dependent upon compliance with the ACCME Accreditation Criteria. The final number of credits may vary from the maximum number indicated above.

Claiming (CME) Credit
Physicians and other health care professionals seeking AMA PRA Category 1 Credit(s)™ for this live continuing medical education activity must complete the CME Request for Credit Survey by November 5, 2018. Certificates will only be issued to those who complete the survey. Your CME certificate will be sent to you via email after the completion of the activity.

Learning Objectives
Physicians and other health care professionals who attend the meeting should be able to summarize the program content, discuss its application in clinical practice, and convey the information to administrators at their centers. As part of the program's learning objectives, all attendees should be able to describe and discuss:

•The evolution of the academic cancer center in the next decade.
•Opportunities in global cancer research.
•Strategies for recognizing and addressing physician burnout.
•Models of care across cancer center networks which promote efforts to integrate treatment services into the community.
•Methods of collecting and integrating Big Data for improved cancer patient care.
•Comprehensiveness, training, and community engagement in the National Cancer Institute’s (NCI) Cancer Center Support Grant (CCSG) application.
•The value of sequencing based approaches in breast and lung cancers.
•Programmatic models which enhance comprehensive patient support and care.
•The impact of evaluating the genetic heterogeneity of phenotypically identical cells and its potential impact on individualized medicine.
•Compliance with the most current NCI CCSG guidelines.
•NCI’s priorities, policies, strategies and goals for the national cancer research enterprise, and their relationship to academic cancer centers.
•Strategies for navigating the changing health care marketplace.
•Developing a CAR T-cell therapy program with an emphasis on intake and management issues, standard operating procedures, and regulatory requirements.
•Progress of the AACI Clinical Research Initiative (CRI) over the last decade.
•Challenges and opportunities for collaboration between academia, government, and the private sector.

Americans with Disabilities Act
It is the policy of the American Association for Cancer Research and the Association of American Cancer Institutes not to discriminate against any person on the basis of disabilities. If you feel you need services or auxiliary aids mentioned in this act in order to fully participate in this continuing education activity, please contact 412-647-6111 or attach a note to your registration form.

Faculty Disclosure
It is the policy of the American Association for Cancer Research and the Association of American Cancer Institutes to require disclosure of financial relationships from individuals in a position to control the content of a CME activity; to identify and resolve conflicts of interest related to those relationships; and to make disclosure information available to the audience prior to the CME activity. Presenters are required to disclose discussions of unlabeled/unapproved uses of drugs or devices during their presentations.

Target Audience
This trans-disciplinary conference is designed for basic and clinical scientists, as well as for physician-scientists from academia, industry, government, and other institutions with interest in innovative systems and technologies for diagnosing, preventing, and treating cancer and its long-term effects.

Leaders of AACI’s academic and freestanding cancer research centers, including cancer center directors, executive administrators, and other top scientific and clinical leaders—leaders from industry and government agencies as well as those of cancer research and advocacy organizations attend the meeting. All attendees have a significant impact on cancer research and patient care. Medical professionals, including oncologists, pharmacists, radiologists, nuclear medicine physicians, nurses, social workers, psychologists, cancer communication specialists, public health leaders, and other faculty members who focus on cancer.